Alia Lynch, PharmD, BCOP

Explore the evolving role of pharmacists in managing EGFR-mutated non-small cell lung cancer and the future of resistance-directed therapies.

Subcutaneous Amivantamab shows promise with reduced infusion reactions and improved patient convenience, potentially transforming treatment experiences.

Pharmacists play a crucial role in implementing novel therapies for non-small cell lung cancer, focusing on education, communication, and patient safety.

Pharmacists play a crucial role in implementing novel cancer therapies, ensuring patient safety, education, and streamlined operations for optimal care.

Healthcare professionals navigate the complexities of sequencing FDA-approved therapies for EGFR-mutated lung cancer, focusing on patient-specific treatment plans.

Discover the innovative dadepotamab deruxtecan, an antibody-drug conjugate offering new hope for EGFR mutant lung cancer patients.

Discover the latest insights on amivantamab's efficacy in non-small cell lung cancer and its impact on treatment guidelines and patient outcomes.

Explore the latest FDA-approved therapies for non-small cell lung cancer, focusing on EGFR mutations and treatment strategies in oncology.

Navigating FDA-Approved EGFR-Targeted Therapies in NSCLC